Recently Updated
What changed and when — corrections, retractions, and other meaningful editorial updates, newest first.
Updates
FDA approves tovorafenib, the first systemic therapy for BRAF-altered pediatric low-grade glioma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA clears AI-powered second-read tool that catches missed prostate cancers on biopsy
Status changed from "Legacy / Unverified" to "In editorial review".
FDA converts tisotumab vedotin’s accelerated approval to full approval for recurrent or metastatic cervical cancer
Status changed from "Legacy / Unverified" to "In editorial review".
Phase 3 ASCENT-07 trial finds no progression-free-survival benefit for sacituzumab govitecan over chemotherapy in HR-positive breast cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves lifileucel, the first tumor-derived T-cell therapy, for advanced melanoma
Status changed from "Legacy / Unverified" to "In editorial review".
National mortality data show a substantial drop in cervical cancer deaths among HPV-vaccinated women in England
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves epcoritamab, a first-in-class bispecific antibody, for relapsed or refractory large B-cell lymphoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves sotorasib plus panitumumab, the first KRAS G12C-targeted combination for colorectal cancer
Status changed from "Legacy / Unverified" to "In editorial review".
A lab-made “molecular glue” reprograms a lymphoma oncogene to trigger cancer-cell self-destruction, in early cell and mouse studies
Status changed from "Legacy / Unverified" to "In editorial review".
FDA grants traditional approval to pirtobrutinib for BTK-inhibitor-pretreated CLL/SLL
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves eflornithine, the first therapy to reduce relapse risk in high-risk pediatric neuroblastoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves Breyanzi as the first CAR T-cell therapy for marginal zone lymphoma
Status changed from "Legacy / Unverified" to "In editorial review".
Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first ctDNA-guided adjuvant immunotherapy, for bladder cancer after surgery
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves blinatumomab in the consolidation phase of B-cell precursor acute lymphoblastic leukemia, regardless of MRD status
Status changed from "Legacy / Unverified" to "In editorial review".
A widely-shared case series claiming a veterinary dewormer treats cancer was retracted — for an undisclosed conflict of interest, not disproven data
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit
Status changed from "Legacy / Unverified" to "In editorial review".
Six-year OlympiA data sustain the adjuvant olaparib survival benefit in BRCA-mutated, HER2-negative early breast cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves Optune Pax, a wearable electric-field device, for locally advanced pancreatic cancer
Status changed from "Legacy / Unverified" to "In editorial review".
Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves zanidatamab for HER2-positive biliary tract cancer, including cholangiocarcinoma
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves the first all-oral combination regimen for older adults with newly diagnosed acute myeloid leukemia
Status changed from "Legacy / Unverified" to "In editorial review".
Lunresertib plus camonsertib produces durable responses in advanced endometrial and ovarian cancer in early trial data
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves perioperative pembrolizumab for head and neck cancer — the first approval for this cancer in 6 years
Status changed from "Legacy / Unverified" to "In editorial review".
Investigational triple-negative breast cancer vaccine shows safety and immune response in phase 1 trial
Status changed from "Legacy / Unverified" to "In editorial review".
Prospective trial finds robotic surgery a safe option for right-sided colon cancer
Status changed from "Legacy / Unverified" to "In editorial review".
FDA approves talquetamab, a first-in-class bispecific antibody, for heavily pretreated multiple myeloma
Status changed from "Legacy / Unverified" to "In editorial review".
First-in-human trial tests ultra-fast “FLASH” proton radiotherapy for painful bone metastases
Status changed from "Legacy / Unverified" to "In editorial review".
Personalized neoantigen vaccine shows no cancer recurrence in small phase 1 kidney cancer trial
Status changed from "Legacy / Unverified" to "In editorial review".